Observational studyArthritis & rheumatology (Hoboken, N.J.)2024
Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study.
Observational study in Arthritis & rheumatology (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Clinical manifestations, prognostic impact, and relapse in polyarteritis nodosa: a systematic review and meta-analysis.Rheumatology international · 2026Pooled it
- Predictors of Immunosuppressive Treatment in Cutaneous Arteritis: Analysis of Clinical Characteristics in 42 Patients.The Journal of dermatology · 2026Article
- Systemic Idiopathic Polyarteritis Nodosa Mimicking Cryoglobulinemic Vasculitis: A Diagnostic Challenge.Cureus · 2026Article
- Temporal artery biopsy in polyarteritis nodosa: a case-based narrative literature review.Clinical rheumatology · 2026Review
- Isaacs syndrome associated with polyarteritis nodosa.BMJ case reports · 2026Article
- Article
- Current and future advances in practice: polyarteritis nodosa and related vasculitides.Rheumatology advances in practice · 2026Review
- Vasculitic fasciitis characterizes a distinct subset of vasculitic myopathy with interferon-gamma signature.Acta neuropathologica · 2025Article
- Polyarteritis nodosa presenting with pancreatic-artery rupture and co-existing MEFV and ADA2 mutation: clinicopathological and genomic insights from a case report.Virchows Archiv : an international journal of pathology · 2025Article
- New avenues in childhood vasculitis.Pediatric rheumatology online journal · 2025Review
- Article
- [Vasculitic involvement of the skeletal muscle and the peripheral nervous system: clinical and neuropathologic perspective].Zeitschrift fur Rheumatologie · 2025Review
- Lethal Gastrointestinal Manifestation and 3D-Reconstructive CT in Systemic Polyarteritis Nodosa (PAN).International journal of rheumatic diseases · 2025Article
- Bridging Gaps and Charting Future Directions in Vasculitis.Journal of clinical medicine · 2024Article
- Diagnostic delays in systemic vasculitides.Rheumatology international · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 20 institutions in 10 countries.
Funding
Abstract
objectiveWe describe the demographics, clinical features, disease course, and survival of polyarteritis nodosa (PAN) through an international collaboration (GLOBAL-PAN).
methodsPatients with PAN were recruited between 1990 and 2020 from observational cohorts of nine countries across Europe, Japan, and North America. Eligibility was retrospectively defined using the European Medicines Agency classification algorithm. Patients with PAN related to hepatitis B virus (n = 12) and two monogenic diseases mimicking PAN, deficiency of adenosine deaminase 2 enzyme (n = 16) or familial Mediterranean fever (n = 11), were excluded. Data regarding organ involvement, relapse, disease-related damage, and survival were analyzed.
resultsThree hundred fifty-eight patients (female:male ratio 174:184), including those with systemic PAN (sPAN, n = 282) and cutaneous PAN (n = 76), were included. Twenty-five were pediatric onset. Mean ± SD age at diagnosis was 44.3 ± 18.1 years. Constitutional symptoms (71.5%), cutaneous involvement (70.5%), musculoskeletal findings (69.1%), and neurologic features (48.0%) were common manifestations. Among patients with sPAN, gastrointestinal involvement and proteinuria over 400 mg/day were reported in 52.2% and 11.2%, respectively. During a median (interquartile range) 59.6 (99.5) months of follow-up, relapse occurred in 48.5% of patients. One, 5- and 10-year survival rates for sPAN were 97.1%, 94.0%, and 89.0%, respectively. Predictors of death for sPAN included age ≥65 years at diagnosis, serum creatinine at diagnosis >140 μmol/L, gastrointestinal manifestations, and central nervous system (CNS) involvement.
conclusionThe spectrum of PAN remains a complex, multifaceted disease. Relapse is common. Age ≥65 years and serum creatinine >140 μmol/L at diagnosis, as well as gastrointestinal and CNS involvement, are independent predictors of death in sPAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.